First Read: Novo Nordisk "New-to-brand GLP-1 prescription trends" (Neutral)

研报英文原文证据摘录

First Read: Novo Nordisk "New-to-brand GLP-1 prescription trends" (Neutral)

for private use by its holder and may not be passed on to third parties or otherwise publicly distributed. USA: Distributed to US persons only by UBS

Financial Services Inc. or UBS Securities LLC, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS BB Corretora de Câmbio, Títulos e Valores

Mobiliários S.A., UBS Asesores México, S.A. de C.V., UBS SuMi TRUST Wealth Management Co., Ltd., UBS Wealth Management Israel Ltd. and UBS Menkul Degerler AS are

affiliates of UBS AG. UBS Financial Services Inc. accepts responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to

US persons. All transactions by a US person in the securities mentioned in this report should be effected through a US-registered broker dealer affiliated with

UBS, and not through a non-US affiliate. The contents of this report have not been and will not be approved by any securities or investment authority in the

United States or elsewhere. UBS Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of

Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not

constitute, advice within the meaning of the Municipal Advisor Rule. For information on the ways in which UBS Securities LLC manages conflicts and maintains

independence of its UBS Global Research product; historical performance information; certain additional disclosures concerning UBS Global Research recommendations; and

terms and conditions for certain third party data used in research report, please visit https://www.ubs.com/disclosures.